Figure 1
Socio-demographic data and tumour characteristics of the patients in the study at baseline (n = 74)_
| Variable | Frequency | Percentage |
|---|---|---|
| Age, years | ||
| <35 | 8 | 10.81% |
| 35–45 | 26 | 35.13% |
| 46–55 | 21 | 28.38% |
| 56–65 | 19 | 25.68% |
| Marital status | ||
| Married | 58 | 78.37% |
| Single | 5 | 6.77% |
| Widow | 11 | 14.86% |
| Body mass index | ||
| Normal weight | 17 | 22.97% |
| Overweight | 26 | 35.17% |
| Obese | 31 | 41.89% |
| Menopausal state | ||
| Pre-menopause | 38 | 51.35% |
| Post-menopause | 36 | 48.65% |
| Family history of breast cancer | ||
| Yes | 15 | 20.27% |
| No | 59 | 79.73% |
| Comorbidity | ||
| Yes | 16 | 21.62% |
| No | 58 | 78.38% |
| Educational level | ||
| Low level | 47 | 63.51% |
| Intermediate level | 18 | 24.32% |
| High level | 9 | 12.16% |
| ECOG performance status | ||
| 0 | 19 | 25.68% |
| 1 | 47 | 63.51% |
| 2 | 8 | 10.81% |
| 3 | 0 | 0.00% |
| 4 | 0 | 0.00% |
| Histological type | ||
| IDC | 67 | 90.54% |
| ILC/mixed IDC/ILC | 7 | 9.46% |
| Clinical stage | ||
| IIB | 10 | 13.52% |
| IIIA | 31 | 41.89% |
| IIIB | 33 | 44.59% |
| Hormone receptor status | ||
| ER and/or PR positive | 63 | 85.14% |
| ER and PR negative | 11 | 14.86% |
| HER2 status | ||
| Positive | 30 | 40.54% |
| Negative | 44 | 59.46% |
Reliability of EORTC QLQ-BR45 Arabic version in female breast cancer patients in Egypt (n = 74)_
| Scale | Cronbach’s α valuea |
|---|---|
| Body image | 0.54 |
| Sexual functioning | 0.85 |
| Breast satisfaction | 0.95 |
| Systemic therapy side effects | 0.63 |
| Arm symptoms | 0.77 |
| Breast symptoms | 0.74 |
| Endocrine therapy symptoms | 0.76 |
| Skin mucosis symptoms | 0.75 |
| Endocrine sexual symptoms | 0.88 |
| Future perspective | Single item |
Multi-trait scaling analysis for convergent and divergent validity of EORTC-QLQ-BR45 Arabic version in female breast cancer patients in Egypt (n = 74)_
| Scale | Subscale | Item–own scale correlationa | Item–other scale correlationa | Scaling success |
|---|---|---|---|---|
| Functional scales | ||||
| Body image | 0.487–0.798 | 0.032–0.638 | 4/4 | |
| Sexual functioning | 0.902–0.924 | 0.001–0.027 | 2/2 | |
| Breast satisfaction | 0.977–0.978 | −0.041–0.03 | 2/2 | |
| Symptoms scales | ||||
| Systemic therapy side effectsb | 0.308–0.743 | 0.002–0.507 | 7/7 | |
| Arm symptoms | 0.765–0.872 | 0.022–0.480 | 3/3 | |
| Breast symptoms | 0.649–0.827 | 0.016–0.308 | 4/4 | |
| Target therapy scales | ||||
| Endocrine therapy symptomsb | 0.397–0.879 | 0.003–0.773 | 10/10 | |
| Skin mucosis symptoms | 0.425–0.796 | 0.055–0.541 | 6/6 | |
| Endocrine sexual symptoms | 0.940–0.959 | 0.004–0.635 | 4/4 |